NYSE: WSTWest Pharmaceutical Services Inc Stock
$351.52-2.96 (-0.84%)
Updated May 15, 2024
WST Price
$351.52
Fair Value Price
N/A
Market Cap
$25.61B
52 Week Low
$310.42
52 Week High
$415.73
P/E
45.83x
P/B
9.55x
P/S
9.93x
PEG
1.82x
Dividend Yield
0.22%
Revenue
$2.93B
Earnings
$568.70M
Gross Margin
37.2%
Operating Margin
23.64%
Profit Margin
19.4%
Debt to Equity
0.34
Operating Cash Flow
$757M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
Jul 31, 2024
Next Dividend
Aug 7, 2024
WST Overview
West Pharmaceutical Services Incorporated manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the U.S. and internationally. Its Proprietary Products segment offers stoppers and seals for injectable packaging systems, and syringe and cartridge components for injectable drug applications. The Contract-Manufactured Products segment manufactures and (automated) assembles devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical and medical device companies. The company was incorporated in 1923 and is headquartered in Exton, PA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how WST scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WST ($351.52) is trading above its intrinsic value of $109.67, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WST is poor value based on its earnings relative to its share price (45.83x), compared to the US market average (31.36x)
P/E vs Market Valuation
WST is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more WST due diligence checks available for Premium users.
Be the first to know about important WST news, forecast changes, insider trades & much more!
WST News
Valuation
WST price to earnings (PE)
For valuing profitable companies with steady earnings
Company
45.83x
Industry
60.55x
Market
31.36x
WST is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
WST is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
WST price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.55x
Industry
3.65x
WST is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WST price to earnings growth (PEG)
For valuing profitable companies with growth potential
WST is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
WST's financial health
Profit margin
Revenue
$695.4M
Net Income
$115.3M
Profit Margin
16.6%
WST's Earnings (EBIT) of $692.20M... subscribe to Premium to read more.
Interest Coverage Financials
WST's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.6B
Liabilities
$921.7M
Debt to equity
0.34
WST's short-term assets ($1.69B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WST's short-term assets ($1.69B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WST's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WST's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$118.2M
Investing
-$90.6M
Financing
-$271.0M
WST's operating cash flow ($756.60M)... subscribe to Premium to read more.
Debt Coverage Financials
WST vs Medical Stocks
West Pharmaceutical Services Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.